Jankovic et al. ‘Therapetuic Uses of Botulinum Toxin’, New England Journal of Medicine, vol. 324, No. 17, pp. 1186-1191, Apr. 1991.* |
Schantz et al. ‘Properties and Use of Botulinum Toxin Andother Microbial Neurotoxins in Medicine’, Microbiological Reviews, vol. 56, No. 1, pp. 80-99, Mar. 1992.* |
File Medline on STN. No. 92055523. Gjerstad et al. ‘[Treatmetn of Focal Dystonia With Boulinum Toxin]. Behandling AV Fokale Dystonier Med Botulinumtoksin’, Tidsskrift For Den Norske Laegeforening, vol. 111, No. 21 pp. 2637-9. Sep. 10, 1991.* |
File Phin on STN. AN No. 92:6599. ‘Athena Files US and Canadian Investigational New Drugs (INDs) for AN-072’ Scrip, No. 1724, p29 (Jun. 1992). Abstract only.* |
File Promt on STN. AN No. 92:546237. ‘Athena Outlines Business Strategy’, Marketletter, ISSN: 0140-4288. Abstract only. (Oct. 5, 1992).* |
Correspondence Dated Dec. 10, 1991 Between William C. Shepherd and Ira Sanders. |
Correspondence Dated Apr. 13, 1992 Between Ira Sanders and Angelika S. Aswad Regarding “Animal Study”. |
Partial Correspondence Dated Apr. 24, 1992 Between Angelika S. Aswad and Dr. Sanders Regarding “Botulinum Toxin to Decrease Salivary Flow”. |
Ambache, J. Physiol. (1951) 113, 1-17. |
Ambache, J. Physiol. (1949) 108, 127-141. |
Brin; Arch. De Neurobiol. 54. Supl. 3 (7-23) 1991. |
Jenzer et al; Schweiz. Med. WSCHR. (1974); 104, 685-693 (w/English translation). |
Poungvarin et al; J. Med. Assoc. Thai. (Apr. 1992) 75 (4) 199-203. |
Greene, Paul E., et al.; Response to Botulinum Toxin F in Seronegative Botulinum Toxin A-Resistant Patients; Movement Disorders; vol. 11, No. 2; pp. 181-184 (Mar. 1996). |
Moyer, E.D., et al.; Effects of Intramuscular Injection of Botulinum Toxin Type B in Nonhuman Primates; Botulinum and Tetanus Neurotoxins-Neurotransmission and Biomedical Aspects; Bibhuti R. Dasgupta, Editor; Plenum Press (1993). |
Price, J., et al.; A Comparative-Study of Tear Secretion in Blepharospasm and Hemifacial Spasm Patients Treated with Botulinum Toxin; Journal of Clinical Neuro-Ophthalmology; vol. 13, No. 1; pp. 67-71 (Mar. 1993). Abstract only. |
Scott, Alan B., et al.; Systemic Toxicity of Botulinum Toxin by Intramuscular Injection in the Monkey; Movement Disorders; vol. 3, No. 4; pp. 333-335 (1988). |
Truong, Daniel D., et al.; BotB (Botulinum Toxin Type B): Evaluation of Safety and Tolerability in Botulinum Toxin Type A-Resistant Cervical Dystonia Patients (Preliminary Study); Movement Disorders; vol. 12, No. 5; pp. 772-775 (Sep. 1997). |
Tsui, J.K., et al.; A Pilot Study on the Use of Botulinum Toxin in Spasmodic Torticollis; The Canadian Journal of Neurological Sciences; vol. 12, No. 4; pp. 314-316 (Nov. 1985). |
Tsui, Joseph K.C., et al.; Local Treatment of Spasmodic Torticollis with Botulinum Toxin; Le Journal Canadien des Sciences Neurologiques; vol. 14, No. 3 (Supplement); pp. 533-535 (Aug. 1987). |
Med Ad News staff; Athena Makes a Wise Move: Medical Advertising News; p. 4 (Nov. 1992). |
U.S. Food and Drug Administration; List of Orphan Designations and Approvals; pp. 1 and 42-46 of 275 (computer search printout dated Jan. 18, 2000). |